title: Multidisciplinary management of pancreatic cancer.
abstract: Pancreatic cancer remains a vexing treatment challenge, with a cure rate that remains just 7%. Two effective regimens--gemcitabine/nab-paclitaxel and FOLFIRINOX--have improved outcomes and are being used earlier in the disease. However, meaningful differences in outcomes may not be realized without novel strategies. Targeting of the immune system is an active area of research.
authors.affiliation: Presented by Margaret A. Tempero, MD, Director of the University of California, San Francisco, Pancreas Center; Professor of Medicine at the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California; and Editor-in-Chief of JNCCN-Journal of the National Comprehensive Cancer Network.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Tempero
mesh_terms: D000418:Albumins / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine